Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...

The authors are to be congratulated for their important bipronged study, which has implications for clinical practice. 7 Their cardinal findings are as follows: (1) The first limb of their article ...